Last reviewed · How we verify
NCT02590250
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
trial testing botulinum toxin Type A in Urinary Incontinence in 250 participants. Completed in 7 August 2017.
7 August 2017
Quick facts
| Lead sponsor | Allergan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 16 December 2015 |
| Primary completion | 7 August 2017 |
| Estimated completion | 7 August 2017 |
| Sites | 12 locations across India |
Drugs / interventions tested
- botulinum toxin Type A (BOTULINUM TOXIN TYPE A) — full drug profile →
Conditions studied
- Urinary Incontinence — all drugs for Urinary Incontinence →
- Overactive Bladder — all drugs for Overactive Bladder →
Sponsor
Allergan — full company profile →
Who can join
18 and older, any sex, with Urinary Incontinence or Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02590250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of botulinum toxin Type A
Trials testing the same drug.
- NCT03193359 — Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine · Phase 3 · withdrawn
- NCT03193346 — BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine · Phase 3 · withdrawn
- NCT02072928 — Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium · completed
- NCT02010775 — Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy · Phase 2 · completed
- NCT01814670 — Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines · Phase 4 · completed
Other recruiting trials for Urinary Incontinence
Currently open trials in the same condition.
- NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
- NCT07105150 — Efficacy of a Video-Based Educational Program on Female Urinary Incontinence · NA · recruiting
- NCT07426861 — Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence · NA · recruiting
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
Other Allergan trials
Trials by the same sponsor.
- NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
- NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
- NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
- NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
- NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02590250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allergan
- Last refreshed: 26 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02590250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing